Roche’s Tecentriq SC Receives the EC’s Approval for Treating Various Cancers
Shots:
- The company’s Tecentriq SC formulation has received marketing authorization for all the indicated cancers of Tecentriq IV. The SC injection will reduce the treatment time from ~30-60mins., when administered IV, to ~7mins.
- The approval was based on the data from the P-IB/III (IMscin001) trial investigating the safety, efficacy and PK of Tecentriq SC vs Tecentriq IV for patients (n=371) with previously treated locally advanced or metastatic NSCLC who failed on prior Pt therapy
- The trial results showed that the ORR, PFS, OS and DoR were the same in the SC vs IV treatment arms with a consistent safety and known profile of Tecentriq IV
Ref: Roche | Image: Roche
Related News:- Roche received the EU’s CHMP Positive Opinion for subcutaneous injection of Tecentriq to treat multiple types of cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
